AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI

AXQ Capital LP bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 41,495 shares of the company’s stock, valued at approximately $227,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its stake in Trevi Therapeutics by 15,969.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company’s stock valued at $48,000 after purchasing an additional 8,783 shares during the last quarter. Strs Ohio acquired a new stake in shares of Trevi Therapeutics during the first quarter worth about $52,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Trevi Therapeutics during the second quarter worth about $56,000. Campbell & CO Investment Adviser LLC purchased a new stake in Trevi Therapeutics in the second quarter valued at approximately $75,000. Finally, Kingswood Wealth Advisors LLC acquired a new position in Trevi Therapeutics in the 2nd quarter worth approximately $80,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Analysts Set New Price Targets

TRVI has been the subject of several research reports. D. Boral Capital restated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a research note on Friday, November 14th. Needham & Company LLC reduced their target price on shares of Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 8th. Leerink Partners boosted their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. B. Riley raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. Finally, Raymond James Financial reduced their price objective on Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating for the company in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.44.

Trevi Therapeutics Stock Performance

TRVI stock opened at $11.36 on Wednesday. Trevi Therapeutics, Inc. has a one year low of $2.36 and a one year high of $12.30. The firm’s fifty day moving average is $10.27 and its 200 day moving average is $8.06. The firm has a market cap of $1.46 billion, a PE ratio of -30.70 and a beta of 0.67.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. Research analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.